Information Provided By:
Fly News Breaks for April 12, 2017
PRTA
Apr 12, 2017 | 15:12 EDT
Cantor analyst William Tanner initiated Prothena with an Overweight and an $86 price target saying he views the company's intrinsic proteinmisfolding and cell-trafficking knowledge as integral to an R&D engine that could yield novel therapies to treat important diseases. Not only does Prothena have Orphan drug candidates NEOD1 and PRX004 for treating amyloidopathies, but Tanner believes the Parkinson's disease and psoriatic arthritis programs has the potential to deliver greater value.
News For PRTA From the Last 2 Days
There are no results for your query PRTA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.